Buy & Sell Neurocrine Biosciences Inc (NBIX) – Neurocrine Biosciences Inc Price Today
Aura AI Summary
Key Stats
- $15.99BMarket Cap
- HealthSector
- -6.53%3M Drawdown
- $15.08BEnterprise Value
- -Dividend Yield
- 9 daysTypical Hold Time
Neurocrine Biosciences Inc (NBIX) is currently valued at a market capitalization of $15.99B, with an enterprise value of $15.08B. Over the past 52 weeks, Neurocrine Biosciences Inc has traded between a low of $123.1 and a high of $167.35, highlighting its annual price range. Over the past three months, Neurocrine Biosciences Inc has recorded a drawdown of -6.53%, reflecting recent price volatility. On average, investors hold Neurocrine Biosciences Inc for approximately 9 days, indicating typical investor behavior on the platform.
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Most Recent News
Investigation launched into Gildan Activewear over alleged revenue inflation and financial engineering.
Bronstein, Gewirtz & Grossman, LLC has opened an investigation into Gildan Activewear following a report accusing the company of inflating revenues by channel stuffing and obscuring financial details through off-balance sheet receivables. The report ...

Infineon wins patent case, stops Innoscience from selling infringing GaN products in Germany
The Munich District Court ruled in favor of Infineon Technologies, prohibiting Chinese company Innoscience from manufacturing, selling, and marketing products that infringe Infineon's patented gallium nitride (GaN) technology in Germany. This marks I...

Amazon plans to sell AI Trainium chips beyond AWS, expanding its AI infrastructure reach.
Amazon is expanding its AI chip strategy by planning to sell its custom Trainium AI chips outside of Amazon Web Services (AWS), targeting third-party data centers. This move aims to compete with NVIDIA in the AI infrastructure market and meets growin...
